DCN exhibits both anti-angiogenic and anti-fibrotic properties, and previous studies have shown that genetic deletion or pharmacological inhibition of GzmB can prevent DCN cleavage and increase DCN levels in several skin disorders [12, 13]. Here, GZMB is linked to skin disorder.